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OBJECTIVE: To evaluate the risk of preeclampsia in
pregnant women with human immunodeficiency virus
(HIV).
METHODS: This is a 26-year population-based retrospec-
tive cohort study. Human immunodeficiency virus–infected
pregnant women were compared with a HIV-negative
comparison group. The primary outcome was the inci-
dence of preeclampsia. We planned subgroup analysis
according to antiretroviral therapy.
RESULTS: A total of 84,725 women were included in the
analysis, of whom 453 were HIV-infected and 84,272 HIV-
negative. Of the 453 HIV-infected women, 301 (66.4%)
received highly active antiretroviral therapy (HAART
group) during pregnancy, whereas 152 (33.6%) did not.
After adjusting for confounders, we found that
HIV-infected women had a significantly higher risk of
preeclampsia (10.2% compared with 4.1%; adjusted odds
ratio [OR] 2.68, 95% confidence interval [CI] 1.96–3.64),
preeclampsia with severe features (4.0% compared with
2.0%; adjusted OR 2.03, 95% CI 1.26–3.28), early-onset
(3.5% compared with 1.4%; adjusted OR 2.50, 95% CI
1.51–4.15) and late-onset preeclampsia (6.6% compared
with 2.6%; adjusted OR 2.64, 95% CI 1.82–3.85), and pre-
term birth at less than 37 weeks of gestation (11.0% com-
pared with 4.7%; adjusted OR 2.50, 95% CI 1.86–3.37)
compared with the comparison group. Human immuno-
deficiency virus–infected women who received HAART
had a significantly higher risk of preeclampsia compared
with women without HIV (13.0% compared with 4.1%;
adjusted OR 3.52, 95% CI 2.51–4.94) and compared with
the non-HAART group (13.0% compared with 4.6%;
adjusted OR 3.08, 95% CI 1.34–5.07). The non-HAART
group had a similar risk compared with women without
HIV (4.6% compared with 4.1%; adjusted OR 1.14, 95%
CI 0.53–2.44).
CONCLUSION: Human immunodeficiency virus–infected
women had an increased risk of preeclampsia. Some of
this risk seems to be linked to HAART.
(Obstet Gynecol 2016;127:1027–32)
DOI: 10.1097/AOG.0000000000001424
P reeclampsia is a pregnancy-related condition thataffects approximately 3–7% of all pregnancies.1 It
is a major cause of maternal and perinatal morbidity
and mortality.2 The pathogenesis of preeclampsia re-
mains largely unknown; however, vascular and
immunologic factors seem to be involved in develop-
ment of preeclampsia.2
The human immunodeficiency virus (HIV) is
a lentivirus that causes HIV infection and acquired
immunodeficiency syndrome.3 Before 1994, when the
use of antiretroviral therapy (ART) was found to pre-
vent perinatal transmission, women with HIV were
often discouraged from getting pregnant and, in many
cases, encouraged to undergo sterilization.4,5 Since that
time, combination ART has decreased both vertical
and sexual transmission dramatically. The develop-
ment and widespread use of potent ART such as highly
active ART (HAART), with the concomitant use of at
least three antiretroviral drugs, has transformed HIV
infection from a near certain death sentence to a chronic
manageable condition, whereby patients who adhere
fully to their medication regimen can have an almost
normal lifespan.6 However, some studies showed that
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preeclampsia and fetal death have increased sharply in
HIV-infected pregnant women receiving HAART.7
The aim of this study was to evaluate the risk of
preeclampsia in HIV-infected pregnant women,
including those receiving HAART.
MATERIALS AND METHODS
This is a 26-year population-based observational
retrospective cohort study. Clinical records of women
who were referred to the Department of Reproductive
Science, University of Naples Federico II (Naples,
Italy) from January 1989 to August 2015 were collected
prospectively in a dedicated database. All charts
recorded in the database were carefully reviewed by
three authors (M.S., L.S., G.S.). All variables reported
were collected on all of the patients included in this
study. Missing data were retrieved by search of the
women’s clinical records. Only women who delivered
at our Division were included in the analysis.
The study was approved by the local institutional
review board, which also checked the quality of the
data set. Data were anonymized before analysis.
Every pregnant woman received standard medical
care and underwent laboratory testing every trimester,
including complete blood count and urine dipstick for
protein and glucose. Routine screening for HIV in
every pregnant woman with unknown serostatus was
carried out. Beginning in December 1996, HAART
was offered to all HIV-positive women during preg-
nancy. All HIV-infected pregnant women were
included in the analysis and were compared with
a comparison group (pregnant women without HIV).
Primary and secondary outcomes were designated
a priori. The primary outcome was the incidence of
preeclampsia. Secondary outcomes included incidence
of preeclampsia with severe features, early-onset (pre-
eclampsia requiring delivery before 34 weeks of
gestation) and late-onset preeclampsia (preeclampsia
requiring delivery at or after 34 weeks of gestation), and
incidence of preterm birth at less than 37 weeks of
gestation. We planned to assess the primary outcome
(incidence of preeclampsia) in subgroup analysis ac-
cording to ART status (HAART or non-HAART).
Highly active ART was defined as the concomitant
use of at least three antiretroviral drugs, consisting of
a combination of two nucleoside reverse transcriptase
inhibitors and either a protease inhibitor or a non-
nucleoside reverse transcriptase inhibitor. Non–highly
active ART included either no ART or suboptimal ther-
apy. Suboptimal (or nonsuppressive) therapy was
defined as concomitant use of fewer than three antire-
troviral drugs, such as monotherapy (zidovudine mono-
therapy) or dual ART (zidovudine plus lamivudine).
We also planned to compare the risk of the primary
outcome (incidence of preeclampsia) in HIV-infected
pregnant women who received HAART during preg-
nancy with those who did not (the non-HAART group).
We also assessed the primary outcome in the subset of
women without chronic hypertension and in the subset
of women with singleton gestations.
Diagnosis and management of preeclampsia and
preeclampsia with severe features were based on Amer-
ican College of Obstetricians and Gynecologists guide-
lines.8 Preeclampsia (ie, preeclampsia without severe
features) was defined as a blood pressure elevation
(140/90 mm Hg or greater on two occasions 4 hours
apart or 160/110 mmHg or greater once) after 20 weeks
of gestation with proteinuria (300 mg or greater on 24-
hour protein or greater than 0.3 protein:creatinine ratio)
or any of the following if proteinuria is not present:
platelets less than 100,000/mL, serum creatinine greater
than 1.1 mg/dL (or doubling of creatinine in the absence
of other renal disease), or aspartate aminotransferase or
alanine aminotransferase at least twice the upper limit of
normal.8 Preeclampsia with severe features was defined
as preeclampsia with any of the following: blood pres-
sure 160/110 mm Hg or greater 4 hours apart on bed
rest (unless on antihypertensive medication), platelets
less than 100,000/mL, doubling of aspartate aminotrans-
ferase or alanine aminotransferase, serum creatinine
greater than 1.1 mg/dL (or doubling of serum creatinine
in the absence of other renal disease), pulmonary edema,
or new cerebral or visual disturbances.8 Our data were
collected prospectively in a dedicated database from
January 1989, but we retrospectively classified pre-
eclampsia and preeclampsia with severe features based
on the new American College of Obstetricians and
Gynecologists guidelines.8
Statistical analysis was performed using SPSS
19.0. Categorical variables were compared using the
x2 or Fisher exact test. Within-group comparison was
undertaken using Wilcoxon and Mann-Whitney tests.
P value ,.05 was considered statistically significant.
The risk of preeclampsia was estimated with multivar-
iate analyses through logistic regression models.
Logistic regression, presented as adjusted odds ratio
(OR) with the 95% of confidence interval (CI), was
performed to correct data for those variables signifi-
cantly different between groups.
The study was performed following the STrength-
ening the Reporting of OBservational studies in
Epidemiology (STROBE) guidelines.9
RESULTS
From January 1989 to August 2015, 84,725 pregnant
women were included, of whom 453 (1.1%) were
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HIV-infected and 84,272 were not HIV-infected
(comparison group) (Fig. 1; Table 1). Out of the
453 HIV-infected women, 301 (66.4%) received
HAART during the pregnancy and 152 (33.6%)
did not (non-HAART group; Table 2). Of the 152
included in the non-HAART group, 52 received no
therapy and 100 suboptimal therapy, including zido-
vudine monotherapy (80/100) and zidovudine plus
lamivudine dual ART (20/100). Most of the
HIV-infected pregnant women included in the non-
HAART group (142/152) delivered before HAART
was available at our division (ie, before December
1996).
After adjusting for confounders statistically
proven (ethnicity and level of education), we found
that HIV-infected women had a significantly higher
risk of preeclampsia (10.2% compared with 4.1%;
adjusted OR 2.68, 95% CI 1.96–3.64), preeclampsia
with severe features (4.0% compared with 2.0%;
adjusted OR 2.03, 95% CI 1.26–3.28), early-onset
(3.5% compared with 1.4%; adjusted OR 2.50, 95%
CI 1.51–4.15) and late-onset preeclampsia (6.6%
compared with 2.6%; adjusted OR 2.64, 95% CI
1.82–3.85), and preterm birth at less than 37 weeks
of gestation (11.0% compared with 4.7%; adjusted OR
2.50, 95% CI 1.86–3.37) compared with the compar-
ison group (Table 3). Human immunodeficiency
virus–infected women without chronic hypertension
had a significantly higher risk of preeclampsia
(10.3% compared with 3.8%; adjusted OR 2.69, 95%
CI 1.99–3.64) as did HIV-infected women with sin-
gleton gestations (10.0% compared with 4.0%;
adjusted OR 2.49, 95% CI 1.87–3.32).
Human immunodeficiency virus–infected women
who received HAART had a significantly higher
risk of preeclampsia compared with women with-
out HIV (13.0% compared with 4.1%; adjusted OR
3.52, 95% CI 2.51–4.94) and compared with the
non-HAART group (13.0% compared with 4.6%;
adjusted OR 3.08, 95% CI 1.34–5.07). The non-
HAART group had a similar risk compared
with women without HIV (4.6% compared with
4.1%; adjusted OR 1.14, 95% CI 0.53–2.44) (Fig.
2). Notably, the incidence of preeclampsia among
Table 1. Characteristics of the Included Women
Variable
HIV-
Infected
(n5453)
Comparison
Group
(n584,272) P
Age (y) 29.165.7 29.5611.4 .14
Ethnicity ,.001
Caucasian 296 (65.3) 67,416 (79.9)
Non-Caucasian* 157 (34.7) 16,856 (20.1)
Nulliparous 107 (23.6) 20,009 (23.7) .59
Multiparous 346 (76.4) 64,263 (76.3) .59
Prepregnancy BMI
(kg/m2)
25.9614.9 25.8612.7 .89
Greater than 30 73 (16.1) 15,168 (18.0) .30
Smoking 99 (21.9) 20,224 (24.0) .29
Chronic hypertension 83 (18.3) 9,057 (21.5) .10
Diabetes mellitus
(including
GDM)
52 (11.5) 10,204 (12.1) .68
Family history of
hypertension†
147 (32.5) 24,856 (29.5) .17
Prior preeclampsia 6 (1.3) 1,201 (1.4) .86
Level of education (y)
Less than 12 51 (11.3) 5,899 (7.0) .04
12–16 271 (59.8) 52,663 (62.5) .24
17 or greater 131 (28.9) 25,710 (30.5) .46
No. of fetuses .49
Singleton 431 (95.1) 79,544 (94.4)
Multiple 22 (4.9) 4,728 (5.6)
ART during
pregnancy
—
No therapy 52 (11.5) —
Suboptimal 100 (22.1) —
Non-HAART 152 (33.6) —
HAART 301 (66.4) —
BMI, body mass index; GDM, gestational diabetes mellitus; ART,
antiretroviral therapy; HAART, highly active antiretroviral
therapy.
Data are mean6standard deviation or n (%) unless otherwise spec-
ified.
Bold indicates statistical significance.
HAART, the concomitant use of at least three antiretroviral drugs (a
combination of two nucleoside reverse transcriptase inhibitors
and either a protease inhibitor or a nonnucleoside reverse
transcriptase inhibitor).
Non-HAART, either no therapy or suboptimal therapy.
Suboptimal therapy, concomitant use of fewer than three antire-
troviral drugs, including monotherapy (zidovudine monother-
apy) or dual therapy (zidovudine plus lamivudine).
* Non-Caucasian ethnicity, including Hispanic, Asian, black
African.
† First-degree family history of hypertension.
Fig. 1. Study algorithm. HIV, human immunodeficiency
virus. *Division of Maternal-Fetal Medicine, Department of
Reproductive Science, School of Medicine, University of
Naples Federico II, Naples, Italy.
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HIV-infected pregnant women started to increase
in 1997 (ie, after the introduction of the HAART;
Fig. 3).
DISCUSSION
This population-based study showed that HIV-infected
women had a significantly higher risk of preeclampsia
compared with women without HIV. The risk was
increased only among those HIV-infected women who
received HAART therapy.
Our study has several strengths. This is a large 26-
year population-based study. The number of the
included women was very high. Human immunode-
ficiency virus–infected and non–infected women were
similar in terms of maternal demographics. Subgroup
analyses were established a priori. All of these ele-
ments enhance the reliability of a study.10,11
The most important limitation of our study is that
this is a retrospective, nonrandomized comparison. We
acknowledge that the subgroup analyses according to
the ART were underpowered; however, this is indeed
an uncommon cohort of women. Human immunode-
ficiency virus-positive women may be more likely to be
diagnosed with preeclampsia as a result of the height-
ened antenatal surveillance or closer monitoring in
labor. We were not able to collect data on neonatal
outcomes and this is a major limitation of the study.
The study period spans 26 years and this raises the
question of practice changes over that time period,
including the management of the women with pre-
eclampsia. We did not distinguish between spontaneous
and indicated preterm birth. However, the increased
risk for preterm delivery among HIV-infected women
may be explained by their increased risk for early-onset
preeclampsia. Human immunodeficiency virus-positive
women who received at least three antiretroviral drugs,
consisting of a combination of two nucleoside reverse
transcriptase inhibitors and either a protease inhibitor
or a nonnucleoside reverse transcriptase inhibitor, were
classified as receiving HAART in our database. There-
fore, comparing a protease inhibitor with a nonnucleo-
side reverse transcriptase inhibitor was not feasible.
Similarly, we did not compare between women with
new-start HAART and those continuing the therapy.
Highly active ART may cause clinical and laboratory
alterations (eg, proteinuria, thrombocytopenia, trans-
aminase, or creatinine elevations), complicating the
diagnosis of preeclampsia; this could have the effect
of falsely elevating their risk of preeclampsia. The
incidence of preeclampsia in the comparison group
was low (approximately 4%) and this could be the result
of ascertainment bias.
Increased access to HAART has substantially
reduced the risk of mother-to-child transmission among
HIV-infected pregnant women worldwide.3–6 Despite
this significant effect, there are some concerns about
Table 2. Characteristics of the Included Human
Immunodeficiency Virus–Infected
Pregnant Women
Variable
HAART
(n5301)
Non-HAART
(n5152) P
Age (y) 28.264.7 29.368.4 .33
Ethnicity .09
Caucasian 210 (69.8) 86 (56.6)
Non-Caucasian* 91 (30.2) 66 (43.4)
Nulliparous 75 (24.9) 32 (21.1) .37
Multiparous 226 (75.1) 120 (78.9) .37
Prepregnancy BMI (kg/m2) 25.9612.7 25.8613.4
Greater than 30
Smoking 48 (15.9) 25 (16.4) .71
Chronic hypertension 54 (17.9) 29 (19.1) .21
Diabetes mellitus (including
GDM)
30 (10.0) 12 (7.9) .11
Family history of
hypertension†
91 (30.2) 56 (36.8) .12
Prior preeclampsia 4 (1.3) 2 (1.3) .92
Level of education (y)
Less than 12 33 (11.0) 18 (11.8) .41
12–16 180 (59.8) 91 (59.9) .87
17 or greater 87 (28.9) 44 (28.9) .94
No. of fetuses .24
Singleton 285 (94.7) 146 (96.1)
Multiple 15 (5.3) 7 (3.9)
Transaminase elevation‡
CD4+ count (microliters)§
500 or greater 129 (42.9) 65 (42.8) .74
200–499 144 (47.8) 72 (47.4) .84
Less than 200 28 (9.3) 15 (9.9) .86
Plasma viral load
(copies/mL)§
Less than 50 69 (22.9) 34 (22.4)
50–399 171 (56.8) 89 (58.6)
400–999 18 (6.0) 15 (9.9)
1,000–9,999 24 (8.0) 13 (8.6)
10,000 or greater 19 (6.3) 1 (0.7)
HAART, highly active antiretroviral therapy; BMI, body mass index;
GDM, gestational diabetes mellitus.
Data are mean6standard deviation or n (%) unless otherwise
specified.
Bold indicates statistical significance.
HAART, the concomitant use of at least three antiretroviral drugs (a
combination of two nucleoside reverse transcriptase inhibitors
and either a protease inhibitor or a nonnucleoside reverse
transcriptase inhibitor).
Non-HAART, either no therapy or suboptimal therapy.
Suboptimal therapy, concomitant use of fewer than three antire-
troviral drugs, including monotherapy (zidovudine monother-
apy) or dual therapy (zidovudine plus lamivudine).
* Non-Caucasian ethnicity, including Hispanic, Asian, black African.
† First-degree family history of hypertension.
‡ Transaminase elevation, doubled of aspartate aminotransferase or
alanine aminotransferase.
§ Measurement closest to delivery during the third trimester.
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the long-term use of HAART on fetal, neonatal, and
maternal outcomes.12–14 In 2002 Wimalasundera et al
reported that the incidence of preeclampsia was lower
in HIV-infected women who received no ART com-
pared with those who received ART.12,13
The biological plausibility to explain our find-
ings, that is, the higher risk of preeclampsia in
women with HIV, is not completely clear. One
hypothesis is that HAART causes preeclampsia by
a direct toxic effect on the liver and on the
kidney.12,13 It is known that the hepatotoxic and
the nephrotoxic effects of antiretroviral may mimic
preeclampsia.14,15 The physiopathology of pre-
eclampsia seems to be linked to vascular, immuno-
logic, and genetic factors as well as to multiple-organ
injury, including liver and kidney.2,16–18 Moreover,
the administration of HAART is reported to
enhance maternal immune reconstitution by reestab-
lishing the mother’s immune response to fetal anti-
gens and consequently making the HIV-women
susceptible to the development of preeclamp-
sia.12,13,16 Therefore, the higher rate of preeclampsia
in the HIV-infected women HAART-treated might
be the result of immune reconstitution induced by
triple ART or an overlap in the clinical manifesta-
tions of the adverse effects of HAART and pre-
eclampsia, or both. Our findings were at odds with
another study, which showed no significant associa-
tion between HIV positivity and preeclampsia; how-
ever, this study did not stratify its data according
to ART.19
Our study adds to the literature new data helpful to
identify women at risk of preeclampsia. Identification
of pregnant women at risk of hypertensive disorders,
including preeclampsia, could potentially improve
pregnancy outcomes and is also important for future
research investigating the potential role of interven-
tions to reduce the prevalence of the disease.20–22
Fig. 2. Incidence of preeclampsia in HIV-negative pregnant
women (4.1%; n584,272) and in HIV-infected pregnant
women stratified by therapy in the non-HAART (highly
active antiretroviral therapy) group (4.6%; n5152) and in
the HAART group (13.0%; n5301). HIV, human immuno-
deficiency virus.
Sansone. Risk of Preeclampsia in HIV-Infected Women. Obstet
Gynecol 2016.
Fig. 3. Incidence of preeclampsia at University of Naples
Federico II from 1989 to 2015. HIV, human immunodefi-
ciency virus.
Sansone. Risk of Preeclampsia in HIV-Infected Women. Obstet
Gynecol 2016.
Table 3. Primary and Secondary Outcomes in the Overall Analysis
Variables
HIV-Infected
(n5453)
Comparison Group
(n584,272)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
Preeclampsia 46 (10.2) 3,416 (4.1) 3.01 (2.21–3.57) 2.68 (1.96–3.64)
Preeclampsia with severe features 18 (4.0) 1,680 (2.0) 2.57 (1.31–3.05) 2.03 (1.26–3.28)
Early-onset preeclampsia 16 (3.5) 1,214 (1.4) 2.87 (1.66–4.07) 2.50 (1.51–4.15)
Late-onset preeclampsia 30 (6.6) 2.202 (2.6) 2.77 (1.91–3.94) 2.64 (1.82–3.85)
Preterm birth at less than 37 wk of
gestation
50 (11.0) 3,982 (4.7) 2.81 (1.94–3.44) 2.50 (1.86–3.37)
HIV, human immunodeficiency virus; OR, odds ratio; CI, confidence interval.
Data are n (%) unless otherwise specified.
Bold indicates statistical significance.
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In summary, HIV-infected pregnant women had
an increased risk of preeclampsia. This risk seems to
be linked at least in part to HAART.
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